Hosted on MSN12mon
Reviving small molecules in the Alzheimer’s pharmaceutical raceThe next layer could be a CAMK2 inhibitor like the company’s preclinical AD-201 to promote synaptic plasticity and memory formation. At some point in the treatment course, AD-401 could be added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback